Prevention of Calcium Oxalate Renal Stones

  • Charles Y. C. Pak
Part of the International Yearbooks of Nephrology book series (IYNE, volume 1)


Once a stone has formed in the urinary tract, it may cause considerable morbidity such as pain, bleeding and infection. Such stone episodes generally recur in most patients suffering from nephrolithiasis(1).


Stone Formation Calcium Oxalate Intestinal Calcium Absorption Potassium Citrate Idiopathic Hypercalciuria 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Coe FL, Keck J, Norton ER. The natural history of calcium urolithiasis, J Am Med Assoc. 238:1519–1523, 1977.CrossRefGoogle Scholar
  2. 2.
    Segura JW, Patterson DE, LeRoy AJ, May GR, Smith LH. Percutaneous lithotripsy. J Urol. 130:1051–1054, 1983.PubMedGoogle Scholar
  3. 3.
    Chaussy C, Brendel W, Schmiedt E. Extracorporeally induced destruction of kidney stones by shock waves. Lancet. 2:1265–1267, 1980.PubMedCrossRefGoogle Scholar
  4. 4.
    Pak CYC. Physiological basis for absorptive and renal hypercalciurias. Am J Phys. 237:F415-F423, 1979.Google Scholar
  5. 5.
    Zerwekh JE, Pak CYC, Kaplan RA, McGuire JL, Upchurch K, Breslau NA, Johnson R. Pathogenetic role of lµ,25-di-hydroxyvitamin D in sarcoidosis and absorptive hypercal-ciuria: Different response to prednisolone therapy. J Clin Endo Metab. 51:381–386, 1980.CrossRefGoogle Scholar
  6. 6.
    Zerwekh JE, Pak CYC. Selective effects of thiazide therapy on serum lµ,25-dihydroxyvitamin D and intestinal calcium absorption in renal and absorptive hypercalciurias. Metabolism. 29:13–17, 1980.PubMedCrossRefGoogle Scholar
  7. 7.
    Barilla DE, Zerwekh JE, Pak CYC. A critical evaluation of the role of phosphate in the pathogenesis of absorptive hypercalciuria. Min Elect Metab. 2:302–309, 1979.Google Scholar
  8. 8.
    Pak CYC, McGuire J, Peterson R, Britton F, Harrod MJ. Familial absorptive hypercalciuria in a large kindred. J Urol. 126:717–719, 1981.PubMedGoogle Scholar
  9. 9.
    Bushinsky DA, Johnston RB, Nalbantian CE, Favus MJ. Increased calcium absorption and retention, without elevated serum 1,25(OH)2D, in genetically hypercalciuric rats. The American Society of Nephrology 20th Annual Meeting, December 13–16, 1987, p 189A.Google Scholar
  10. 10.
    Pak CYC. Pathogenesis of hypercalciuria. IN: Peck WA, ed. Bone and Mineral Research/4. New York: Elsevier, pp. 303–334, 1986.Google Scholar
  11. 11.
    Pak CYC. Pathogenesis, consequences and treatment of the hypercalciuric states. Seminars in Nephrology. 1:356–365, 1981.Google Scholar
  12. 12.
    Coe FL, Canterbury JM, Firpo JJ, Reiss E. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. J Clin Invest. 52:134–141, 1973.PubMedCrossRefGoogle Scholar
  13. 13.
    Sakhaee K, Nicar MJ, Brater DC, Pak CYC. Exaggerated natriuretic and calciuric response to hydrochlorothiazide in renal hypercalciuria but not in absorptive hypercalciuria. J Clin Endo and Metab. 61:825–829, 1985.CrossRefGoogle Scholar
  14. 14.
    Barilla DE, Townsend J, Pak CYC. An exaggerated augmentation of renal calcium excretion following oral glucose ingestion in patients with renal hypercalciuria. Invest Urol. 15:486–488, 1978.PubMedGoogle Scholar
  15. 15.
    Pak CYC, Galosy RA. Fasting urinary calcium and adenosine 3′-5′-monophosphonate: A discriminant analysis for the identification of renal and absorptive hypercalciuria. J Clin Endo Metab. 48:260–265, 1979.CrossRefGoogle Scholar
  16. 16.
    Lawoyin S, Sismilich S, Browne R, Pak CYC. Bone mineral content in patients with primary hyperparathyroidism, osteoporosis, and calcium urolithiasis. Metab. 28:1250–1254, 1979.CrossRefGoogle Scholar
  17. 17.
    Henneman PH, Benedict PH, Forbes AP. Idiopathic hypercalciuria. NE J Med. 259:801–807, 1958.Google Scholar
  18. 18.
    Kaplan RA, Haussler MR, Deftos LF, Bone H, Pak CYC. The role of 1µ, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest. 59:756–760, 1977.PubMedCrossRefGoogle Scholar
  19. 19.
    Shen FH, Baylink DJ, Nielson RL, Sherrard DJ, Ivey JL, Haussler MR. Increased serum 1,25-dihydroxyvitamin D in idiopathic hypercalciuria. J Lab Clin Med. 90:955–962, 1977.PubMedGoogle Scholar
  20. 20.
    Gray RW, Wilz DR, Caldas AE, Lemann J. The importance of phosphate in regulating plasma l,25-(OH)2vitamin D levels in humans: Studies in healthy subjects, in calcium-stone formers and in patients with primary hyperparathyroidism. J Clin Endo Metab. 45:299–306, 1977.CrossRefGoogle Scholar
  21. 21.
    Bordier R, Ryckewart A, Gueris J, Rasmussen HR. On the pathogenesis of so-called idiopathic hypercalciuria. Am J Med. 63:398–409, 1977.PubMedCrossRefGoogle Scholar
  22. 22.
    Insogna KL, Broadus AE, Dreyer BE, Ellison AF, Gertner JM. Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. J Clin Endo Metab. 61:490–495, 1985.CrossRefGoogle Scholar
  23. 23.
    Coe FL, Favus MJ, Crockett T, Strauss AL, Parks MB, Porat A, Gantt CL, Sherwood LM. Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25-(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med. 72:25–32, 1982.PubMedCrossRefGoogle Scholar
  24. 24.
    Buck AC, Lote CJ, Sampson WF. The influence of renal prostaglandins on urinary calcium exretion in idiopathic urolithiasis. J Urol. 129:421–426, 1983.PubMedGoogle Scholar
  25. 25.
    Coe FL, Kavalach AG. Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. NE J Med. 291:1344–1350, 1974.CrossRefGoogle Scholar
  26. 26.
    Smith LH, Fromm H, Hofmann AF. Acquired hyperoxaluria, nephrolithiasis and intestinal disease. NE J Med. 286:1371–1375, 1972.CrossRefGoogle Scholar
  27. 27.
    Simpson DP. Regulation of renal citrate metabolism by bicarbonate ion and pH: Observations in tissue slices and mitochondria. J Clin Invest. 16:225–238, 1967.CrossRefGoogle Scholar
  28. 28.
    Preminger GM, Sakhaee K, Skurla C, Pak CYC. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol. 134:20–23, 1985.PubMedGoogle Scholar
  29. 29.
    Rudman D, Dedonis JL, Fountain MT, Chandler JB, Gerron GG, Fleming GA, Kutner MH. Hypocitraturia in patients with gastrointestinal malabsorption. NE J Med. 303:657–661, 1980.CrossRefGoogle Scholar
  30. 30.
    Pak CYC, Peterson R, Sakhaee K, Fuller C, Preminger G, Reisch J. Correction of hypocitraturia and prevention of stone formation by combined thiazide and potassium citrate therapy in thiazide-unresponsive hypercalciuric nephrolithiasis. Am J Med. 78:284–288, 1985.CrossRefGoogle Scholar
  31. 31.
    Breslau NA, Brinkley L, Hill KD, Pak CYC. Relationship role of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endo Metab. 66:140–146, 1988.CrossRefGoogle Scholar
  32. 32.
    Sakhaee K, Nigam S, Snell P, Hsu MC, Pak CYC. Assessment of the pathogenetic role of physical exercise in renal stone formation. J Clin Endo Metab. 65:974–979, 1987.CrossRefGoogle Scholar
  33. 33.
    Pak CYC, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kid Int. 30:422–428, 1986.CrossRefGoogle Scholar
  34. 34.
    Broadus AE, Dominguez M, Bartter FC. Pathophysiological studies in idiopathic hypercalciuria: Use of an oral calcium tolerance test to characterize distinctive hypercalciuric subgroups. J Clin Endo Metab. 47:751–760, 1978.CrossRefGoogle Scholar
  35. 35.
    Pak CYC, Kaplan RA, Bone H, Townsend J, Waters 0. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. NE J Med. 292:497–500, 1975.CrossRefGoogle Scholar
  36. 36.
    Pak CYC, Britton F, Peterson R, Ward D, Northcutt C, Breslau NA, McGuire J, Sakhaee K, Bush S, Nicar M, Norman D, Peters P. Ambulatory evaluation of nephrolithiasis: Classification, clinical presentation and diagnostic criteria. Am J Med. 69:19–30, 1980.PubMedCrossRefGoogle Scholar
  37. 37.
    Pak CYC, Smith LH, Resnick MI, Weinerth JL. Dietary management of idiopathic calcium urolithiasis. J Urol. 131:850–852, 1984.PubMedGoogle Scholar
  38. 38.
    Pak CYC, Sakhaee K, Crowther C, Brinkley L. Evidence justifying a high fluid intake in treatment of nephrolithiasis. Ann Int Med. 93:36–39, 1980.PubMedGoogle Scholar
  39. 39.
    Pak CYC, Peters P, Hurt G, Kadesky M, Fine M, Reisman D, Splann F, Caramela C, Freeman A, Britton F, Sakhaee K, Breslau NA. Is selective therapy of recurrent nephrolithiasis possible? Am J Med. 71:615–622, 1981.PubMedCrossRefGoogle Scholar
  40. 40.
    Pak CYC, Holt K, Zerwekh JE. Attenuation by monosodium urate of the inhibitory effect of glycosaminoglycans on calcium oxalate nucleation. Invest Urol. 17:138–140, 1979.PubMedGoogle Scholar
  41. 41.
    Brickman AS, Massry SG, Coburn JW. Changes in serum and urinary calcium during treatment with hydrochlorothiazide studies on mechanisms. J Clin Invest. 51:945–954, 1972.PubMedCrossRefGoogle Scholar
  42. 42.
    Preminger GM, Pak CYC. Eventual attenuation of hypocalciuric response to hydrochlorothiazide in absorptive hypercalciuria. J Urol. 137:1104–1109, 1987.PubMedGoogle Scholar
  43. 43.
    Nicar MJ, Peterson R, Pak CYC. Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis, J Urol. 131:430–433, 1984.PubMedGoogle Scholar
  44. 44.
    Pak CYC. A cautious use of sodium cellulose phosphate in the management of calcium nephrolithiasis. Invest Urol. 19:187–190, 1981.PubMedGoogle Scholar
  45. 45.
    Smith LH, Thomas WC Jr, Arnaud CD. Orthophosphate therapy in calcium renal lithiasis. IN: Delatte LC, Rapado A, Hodgkinson A, eds. Urinary calculi. Basel, S. Karger. pp 188–197, 1973.Google Scholar
  46. 46.
    Pak CYC, Holt K, Zerwekh J, Barilla DE. Effects of ortho-phosphate therapy on the crystallization of calcium salts in urine. Min Elect Metab. 1:147–154, 1978.Google Scholar
  47. 47.
    Van Den Berg J, Kumar R, Wilson DM, Heath H III, Smith LH. Orthophosphate therapy decreases urinary calcium excretion and serum 1,25-dihydroxyvitamin D concentrations in idiopathic hypercalciuria. J Clin Endo Metab. 51:998–1001, 1980.CrossRefGoogle Scholar
  48. 48.
    Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. NE J Med. 315:1386–1389, 1986.CrossRefGoogle Scholar
  49. 49.
    Pak CYC, Peterson R. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Int Med. 146:863–867, 1986.CrossRefGoogle Scholar
  50. 50.
    Pak CYC, Fuller C, Sakhaee K, Preminger GM, Britton F. Long term treatment of calcium nephrolithiasis with potassium citrate. J Urol. 134:11–19,1985.PubMedGoogle Scholar
  51. 51.
    Pak CYC, Fuller C. Idiopathic hypocitraturic calcium oxalate nephrolithiasis successfully treated with potassium citrate. Ann Int Med. 104:33–37, 1986.PubMedGoogle Scholar
  52. 52.
    Preminger GM, Sakhaee K, Pak CYC. Hypercalciuria and altered intestinal calcium absorption occurring independently of vitamin D in distal renal tubular acidosis. Metab. 36:176–179, 1987.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • Charles Y. C. Pak
    • 1
  1. 1.Department of Internal Medicine, Southwestern Medical School at DallasCenter on Mineral Metabolism and Clinical ResearchDallasUSA

Personalised recommendations